iShares Biotechnology ETF

IBB

Market cap $8.05B

LONDON--(BUSINESS WIRE)---- $IBB #AVLSOM3--AV Laboratories, a science-led skincare company founded by pioneers in IVF solutions, regenerative medicine, and stem cell therapy, today announced it will exhibit at the 42nd Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE 2026, taking place in London from 5 - 8 July 2026. The company will welcome clinicians, embryologists, fertility specialists, researchers, partners, and industry participants at Booth A22. “ESHRE is deeply personal.

The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Locking in profits while you have them can help avoid downturns.

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund launched on June 19, 2006.

The iShares Biotechnology ETF (IBB) was launched on 02/05/2001, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

Biotech has reasserted itself over the past year as drug approvals,

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on February 5, 2001.

After a 50%+ run from lows last April through highs in mid-January, the Biotech group has been trending sideways over the last few months. Biotech hasn't garnered much attention lately, with all the coverage of the Iran War and the AI Doom trade that's been taking down software stocks even as AI infrastructure stocks continue to surge.

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded.